ISIN | LU2207278669 |
---|---|
Valor Number | 114371863 |
Bloomberg Global ID | |
Fund Name | Kieger Impact Healthcare Fund Class R USD Accumulating |
Fund Provider |
Kieger AG
Kieger AG Limmatstrasse 264, CH-8005 Zürich Phone: +41 44 444 18 44 Web: https://kieger.com/ E-Mail: info@kieger.com |
Fund Provider | Kieger AG |
Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals ("SDGs"). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 87.16 USD | 07.05.2025 |
---|---|---|
Previous Price * | 88.04 USD | 06.05.2025 |
52 Week High * | 97.97 USD | 16.07.2024 |
52 Week Low * | 81.01 USD | 08.04.2025 |
NAV * | 87.16 USD | 07.05.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 75,133,712 | |
Unit/Share Assets *** | 1,733 | |
Trading Information SIX |
YTD Performance | +0.46% |
31.12.2024 - 07.05.2025
31.12.2024 07.05.2025 |
---|---|---|
YTD Performance (in CHF) | -8.89% |
31.12.2024 - 07.05.2025
31.12.2024 07.05.2025 |
1 month | +7.49% |
07.04.2025 - 07.05.2025
07.04.2025 07.05.2025 |
3 months | -7.57% |
07.02.2025 - 07.05.2025
07.02.2025 07.05.2025 |
6 months | -3.31% |
07.11.2024 - 07.05.2025
07.11.2024 07.05.2025 |
1 year | -7.88% |
07.05.2024 - 07.05.2025
07.05.2024 07.05.2025 |
2 years | -12.84% |
06.07.2023 - 07.05.2025
06.07.2023 07.05.2025 |
3 years | - | - |
5 years | - | - |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Gilead Sciences Inc | 3.68% | |
---|---|---|
Abbott Laboratories | 3.65% | |
Revvity Inc | 3.49% | |
Novo Nordisk AS Class B | 3.47% | |
Inspire Medical Systems Inc | 3.44% | |
Hikma Pharmaceuticals PLC | 3.34% | |
ResMed Inc | 3.33% | |
Amplifon SpA Az nom Post Frazionamento | 3.33% | |
Intra-Cellular Therapies Inc | 3.32% | |
Exact Sciences Corp | 3.30% | |
Last data update | 28.02.2025 |
TER *** | 2.22% |
---|---|
TER date *** | 30.09.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 2.00% |
Ongoing Charges *** | 2.22% |
SRRI ***
|
|
SRRI date *** | 30.04.2025 |